Business
Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity
Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrat...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n \n \n \n Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:1pt; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n \n \n \n \n \n \n New insights into pelareorep's immune-related mechanism of action demonstrate it stimulates an innate immune response that in turn triggers adaptive anti-tumor immunity\n \n \n Specificity for tumor cells compared to normal cells likely results from the impairment of viral detection/interferon responses in malignant cells\n \n \n Canada NewsWire\n \n \n \n \n \n SAN DIEGO\n \n and\n \n CALGARY, AB\n \n ,\n \n March 17, 2022\n \n /CNW/ -- Oncolytics Biotech\n \n ®\n \n Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal\n \n Immunology\n \n . The paper, entitled \"Oncolytic virus treatment differentially affects the CD56\n \n dim\n \n and CD56\n \n bright\n \n NK cell subsets\n \n in vivo\n \n and regulates a spectrum of human NK cell activity,\" was published in collaboration with researchers at several prestigious institutions, including the University of\n \n Leeds School\n \n of Medicine and the Institute of Cancer Research,\n \n London\n \n . A link to the paper can be found by\n \n clicking here\n \n .\n \n \n \n \n \n Described in the paper are\n \n in vitro\n \n studies evaluating pelareorep's effects on Natural Killer (NK) cells as well as analyses of blood samples from patients with colorectal liver metastases taken prior to and after treatment with pelareorep. Results showed pelareorep treatment led to the activation of NK cells, which are known to directly kill cancer cells while stimulating adaptive anti-tumor immunity. The beneficial effects ...